Merck (NYSE:MRK) Reports Strong Phase 3 Results For WINREVAIR In PAH Treatment
Merck (NYSE:MRK) recently presented promising results from the Phase 3 ZENITH trial for its drug WINREVAIR, but the company's stock performance over the past month tells a different story, declining ...
Is Merck Stock a Bargain Buy?
Despite this potential, the stock has fallen by 25% in the past 12 months -- so is it a bargain buy right now? During the ...
Is Weakness In Merck & Co., Inc. (NYSE:MRK) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 7.2% ...
Merck & Co., Inc. (MRK): Among Incredibly Cheap Dividend Stock to Buy Now
We recently published a list of 12 Incredibly Cheap Dividend Stocks to Buy Now. In this article, we are going to take a look ...
Merck & Co.: Looming Patent Expiries For Key Drugs Weaken Longer-Term Outlook
Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.
Merck & Co. Inc. stock outperforms competitors on strong trading day
Merck & Co. Inc. closed 33.72% short of its 52-week high of $134.63, which the company achieved on June 25th.
Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy
Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...
Which Dow Jones Stock Is Cheaper, Amgen or Merck?
Based on Wall Street analyst estimates for 2025 EPS, Amgen trades at 15 times its projected earnings, while Merck sits at a ...
Merck & Co. Inc. stock underperforms Tuesday when compared to competitors
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Merck & Co's Options: A Look at What the Big Money is Thinking
The general mood among these heavyweight investors is divided, with 63% leaning bullish and 36% bearish. Among these notable ...